【摘要】 【目的】评价通心络胶囊治疗脑血管病的疗效与安全性。【方法】计算机检索中国期刊全文数据库(1996-2006年5月)、中国优秀博硕士学位论文全文数据库(1999-2006年5月)、MEDLINE(1996-2006年5月)、Cochrane图书馆,手工检索初步入选的所有文献,获取并评价通心络胶囊治疗脑血管病的随机对照试验(RCT)文献,然后分别采用SAS统计分析软件、RevMan 4.2软件进行Meta分析。【结果】共纳入37篇随机对照研究,3336例患者,其中通心络胶囊组1764例,对照组1572例。在总有效率方面,31个RCT的Meta分析结果显示,两组间差异有统计学意义(P<0.01);在神经功能缺损评分方面,按病种分类作亚组分析时,7个治疗急性脑梗塞的RCT研究显示,两组差异有统计学意义(P<0.05)。不良反应极少发生,未见明显毒副作用。【结论】现有的证据表明,通心络与其他药物比较,可以提高脑血管病患者的治疗总有效率。受纳入研究的质量和数量限制,通心络胶囊治疗脑血管病的疗效与安全性需要更多高质量的、大样本的、双盲的随机对照试验加以证实。更多还原

【Abstract】 【Objective】To assess the efficacy and safety of Tongxinluo Capsules for cerebrovascular disorders by meta analysis.【Methods】Randomized controlled trials(RCT) of Tongxinluo Capsules for cerebrovascular disorders were got by searching China Journal Full-text Database(from 1996 to May,2006),China Best Doctoral and Master’s Dissertations(from 1996 to May,2006),MEDLINE(from 1996 to May,2006),and Cochrane Library with computer,and were screened by manual search.RevMan 4.2 software and SAS were used in Meta-analysis.【Results】Thirty seven RCT were included,in which involved 2791 patients.Among them,1764 patients were treated with Tongxinluo Capsules,and other 1572 served as the controls. Meta-analysis results showed that the difference of the total efficacy in 31 RCT was significant(P<0.01),and the difference of neurological deficit in 7 RCT of Tongxinluo Capsules for cerebral infarction was also significant(P<0.05).Adverse reactions were scarcely found,and no obvious toxic and side effect was found.【Conclusion】The present evidence indicates that Tongxinluo Capsules exert a higher therapeutic effect rate for cerebrovascular disorders.However,to obtain more profound evidences,more high-quality,large-sized and double blind RCT are still required to prove the efficacy and the safety.更多还原